Piramal Pharma Solutions Thursday said it has invested USD 10 million (around Rs 69 crore) to expand its high-potency active pharmaceutical ingredients (HPAPIs) capability in its Riverview facility in the US.
The new wing at the Riverview site is dedicated to the production of HPAPIs with low occupational exposure levels (OELs), Piramal Pharma Solutions said in a statement.
Piramal Pharma Solutions Chief Executive Officer Vivek Sharma said: "We are one of only a few companies in the contract development and manufacturing market that have the capability to produce HPAPIs at such low OELs."
The expansion enhances the company's ability to serve the growing antibody drug conjugate market, the statement said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
